Michael Rosenberg is a Cardiology physician. ClinicalTrials.gov lists 3 registered studies matched to this name.
Overview
Scholarship
indexed output and impact (OpenAlex)Research metrics aren't shown for this record. Either we found no confident publication match for this name, or more than one physician shares the matched author record. We'd rather show nothing than someone else's numbers. Why? →
Clinical & industry
trials, payments and federal fundingContact
The practice address and phone this provider lists in the federal NPPES (CMS) registry.
Practice address
2300 Western Ave
Manitowoc, WI 542203712
Telephone
920-320-3000Registry record last updated 27 Mar 2015.
Clinical trials
- Use of Device Data to Predict Frailty in Individuals
Sponsor: University of Colorado, Denver
- Predicting Rupture of AAA by Anatomic and Hemodynamic Markers
Sponsor: University of Minnesota
- Nutritional Supplementation With Agmatine Sulfate During Small Fiber Neuropathy
Sponsor: JFK Medical Center
Registered studies on ClinicalTrials.gov where the overall official or a site investigator name-matches this physician, confirmed against known institution/geography. Latest few shown; the full list is part of the full profile.
Industry payments
39 companies reported payments to CMS in program years 2021 onward. These are public disclosures, not judgments. The latest:
- BIOTRONIK INC.Program year20254 payments
- GE HEALTHCAREProgram year20251 payment
- Becton, Dickinson and CompanyProgram year20251 payment
Payment records matched to this physician's NPI in CMS Open Payments, program years 2021 onward.
Medicare prescribing footprint (2024)
The drugs this prescriber writes for Medicare patients, grouped by drug class and therapeutic area. Every percentage is a share of their total prescribing, so you can see what they prescribe most. These are proportions, not patient counts or dollar amounts. No condition is inferred: the claims record what was prescribed, never why.
Cardiovascular
70.7%Beta blocker18.3%Metoprolol Succinate55%Carvedilol26%Metoprolol Tartrate13%Sotalol6%Atenolol2%Part D<11 patientsStatin15.8%Rosuvastatin Calcium50%Atorvastatin Calcium47%Simvastatin4%Part D<11 patients+ 16 more classes in this area
Blood & clotting
23.8%P2Y12 inhibitor14.4%Clopidogrel75%Brilinta25%Part D≥124 patientsFactor Xa inhibitor8.4%Xarelto59%Eliquis41%Part D≥45 patients+ 1 more class in this area
Metabolism & gastrointestinal
5.5%SGLT2 inhibitor4.3%Jardiance50%Farxiga44%Dapagliflozin7%Part D<11 patientsPotassium supplement1.2%Potassium Chloride71%Klor-Con M2029%Part D<11 patients
Drug classes come from the WHO ATC and U.S. National Library of Medicine (RxClass) classifications; prescribing counts come from the CMS Medicare Part D Prescribers file. Each drug is counted once, under its primary class. Medicare fee-for-service only, so no Medicare Advantage, commercial, or pediatric prescribing is included. CMS publishes this data about 17 months after the fact.
Similar KOLs
Other experts from the same institution or the same specialty.
Gregory Y.H. Lip
Medical University of Białystok
Mika Kivimäki
University of Helsinki
Salim Yusuf
Population Health Research Institute
Victoria Delgado
Institute of Molecular Bioimaging and Physiology
A basic profile from our physician directory: identity and practice contact from the federal NPPES registry, research from OpenAlex, trials from ClinicalTrials.gov, payments from CMS Open Payments — shown itemized where we have matched records, as a count where we only have a total. This person hasn't been through our full identity-adjudication pipeline yet, so funding, congress activity and public presence aren't shown. Absence of a section means “not yet looked,” never “none found.”